Med Tech Innovators Press Release

By
Kari Cao
June 23, 2025
5 min read
News & Press
Share this post

RenewRx Selected for 2025 MedTech Innovator Cohort, Pioneering Scalable Solutions for Maternal  Diabetes Care

Denver, CO – [June 7th, 2025] RenewRx, a digital health platform transforming care for pregnant  patients with diabetes, has been selected as one of just 65 startups worldwide to join the  prestigious 2025 MedTech Innovator Cohort—chosen from a competitive pool of over 1,450  applicants. MedTech Innovator (MTI) is the world’s largest accelerator for medical technology startups. The highly competitive four-month program provides participants with world-class mentorship, strategic guidance, and access to a robust network of investors, providers, payers, manufacturers, and industry experts.

This recognition positions RenewRx as a leading innovation at the intersection of maternal health,  digital coaching, and chronic disease management. As part of the MedTech Innovator Accelerator,  RenewRx will receive customized mentorship, exclusive access to top MedTech investors and  strategic partners, and a featured spotlight at The MedTech Conference 2025 in San Diego. We are thrilled to have the RenewRx team in our 2025 cohort of the MedTech Innovator Accelerator," said Nicole Black, PhD, MedTech Innovator Program Director. "This year’s selection process was our most competitive yet, with an acceptance rate of just 4% across multiple evaluation stages. We’re especially pleased to see greater representation of innovations in women’s health, and we look forward to supporting RenewRx as they expand their reach within OB/GYN networks nationwide.

“Diabetes in pregnancy is one of the fastest-growing—and most overlooked—challenges in  women’s health,” said Kari Cao, Founder & CEO of RenewRx. “RenewRx helps bridge the gaps  between visits, reduce complications, and bring scalable, personalized care to a population that’s  too often left behind.”

RenewRx supports both patients and providers through an integrated care model that includes:

A patient-facing app with AI-powered meal tracking, continuous glucose monitor (CGM)  integration, and personalized 1:1 habit building coaching and curriculum.  

A provider dashboard that streamlines remote patient monitoring (RPM), surfaces decision ready insights, and enables billing for reimbursable care

Early outcomes show:

• 95% patient retention

• Lower-than-average C-section and NICU rates

• Up to $1,000/month in new, recurring insurance revenue per patient

RenewRx is currently the standard of care at a major maternal-fetal medicine (MFM) practice  spanning five locations and is negotiating a national enterprise rollout with the largest high risk  OB/GYN (MFM) group in the U.S.

About MedTech Innovator

MedTech Innovator is the world’s largest accelerator of medical device, digital health, and diagnostic companies. Its mission is to improve human health by accelerating the growth of companies transforming patient care. MTI has been a catalyst for groundbreaking healthcare solutions, sourcing nearly 14,000 applicants and fostering the growth of over 700 graduates. Alumni have collectively raised $10 billion in follow-on funding and introduced 400+ products to the market, improving the health of millions worldwide. For more information about MedTech Innovator, its annual programs, portfolio of industry-leading startups, and insights on trends, visit www.medtechinnovator.org.

About RenewRx

RenewRx is redefining prenatal care for high-risk pregnancies by empowering clinics to deliver  proactive, data-driven support to patients with gestational or preexisting diabetes. By integrating  lifestyle coaching, biometric insights, and turnkey billing tools, RenewRx enables better outcomes  and sustainable revenue—within a system that too often underfunds women’s health.

To learn more, visit: www.renewrx.health

Press Contact

Kelly Carter

Email: kelly@renewrx.health

Social: @renewrx_health

#MedTechInnovator2025 | #MaternalHealth | #DiabetesInPregnancy | #PrenatalCareRe imagined

Sign up for our newsletter

Lorem ipsum dolor sit amet, consectetur adipiscing elit.

By clicking Sign Up you're confirming that you agree with our Terms and Conditions.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.